×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT0607296
clinical
1,017 words
KG: COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
2026-03-27
kind:clinical-trial
section:clinical-trials
state:published
Contents
COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
Knowledge Graph
Related Hypotheses (23)
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci
Score: 0.45
The Glial Ketone Metabolic Shunt Hypothesis
Score: 0.40
Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Score: 0.69
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Microbial Inflammasome Priming Prevention
Score: 0.58
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Adenosine-Astrocyte Metabolic Reset
Score: 0.56
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.48
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.42
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.39
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.38
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Show 18 more
Related Analyses (8)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 3 more
Related Experiments (22)
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.95
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Show 17 more
Knowledge Graph (2 edges)
COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
references
BDNF
COMMETS - Semaglutide for MCI/Metabolic Syndrome (NCT06072963)
references
NLRP3